Wednesday, June 4, 2025

The #hemagglutinin proteins of clades 1 and 2.3.4.4b #H5N1 #HPAI viruses exhibit comparable attachment patterns to #avian and #mammalian tissues

Abstract

The global spread of the A/goose/Guangdong/1/96-lineage H5N1 highly pathogenic avian influenza (HPAI) viruses is accompanied by an expanded host range and the establishment of sustained viral transmission among dairy cattle. To evaluate if the evolving H5N1 viruses have changed tissue tropism over time, we compared the binding patterns of recombinant hemagglutinin (HA) proteins derived from clade 1 (A/Vietnam/1203/04, H5VN) and circulating clade 2.3.4.4b viruses detected from a wild bird (A/Eurasian Teal/Hong Kong/AFCD-HKU-23-14009-01020/2023, H5HK) and dairy cattle (A/bovine/Ohio/B24OSU-439/2024, H5OH). The HA protein of A(H1N1)pdm09 virus was included for comparison. Using bio-layer interferometry, H1 protein preferentially bound to the 2,6-linked sialoside 6'SLNLN while H5 proteins preferentially bound to the 2,3-linked sialoside 3'SLN. H5OH showed higher binding affinity to 3'SLN than H5HK and H5VN. The attachment pattern of H1 and H5 proteins to the respiratory tissues of different species and dairy cattle mammary glands were evaluated. Compared to the H1 protein, H5 proteins showed stronger binding to the lung epithelial cells of cat, cattle, chicken, ferret, human, and pig, and the clade 2.3.4.4b H5 proteins exhibited increased binding to pig and cattle bronchial epithelial cells. All H5 proteins attached to the alveolar and cistern epithelial cells in mammary glands where α2,3-linked and α2,6-linked sialyl glycans were detected by Maackia amurensis lectin II and Sambucus Nigra Lectin, respectively. Taken together, the HA proteins of clade 1 and 2.3.4.4b H5N1 viruses generally share comparable attachment patterns to avian and mammalian tissues, despite of evolving into antigenically distinct clades over the past 3 decades.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.06.02.657404v1

____

#SARS-CoV-2 infection #enhancement by #amphotericin B: implications for disease management

ABSTRACT

Severe coronavirus disease 2019 (COVID-19) patients who require hospitalization are at high risk of invasive pulmonary mucormycosis. Amphotericin B (AmB), which is the first-line therapy for invasive pulmonary mucormycosis, has been shown to promote or inhibit replication of a spectrum of viruses. In this study, we first predicted that AmB and nystatin had strong interactions with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins using in silico screening, indicative of drugs with potential therapeutic activity against this virus. Subsequently, we investigated the impact of AmB, nystatin, natamycin, fluconazole, and caspofungin on SARS-CoV-2 infection and replication in vitro. Results showed that AmB and nystatin actually increased SARS-CoV-2 replication in Vero E6, Calu-3, and Huh7 cells. At optimal concentrations, AmB and nystatin increase SARS-CoV-2 replication by up to 100- and 10-fold in Vero E6 and Calu-3 cells, respectively. The other antifungals tested had no impact on SARS-CoV-2 infection in vitro. Drug kinetic studies indicate that AmB enhances SARS-CoV-2 infection by promoting viral entry into cells. Additionally, knockdown of genes encoding for interferon-induced transmembrane (IFITM) proteins 1, 2, and 3 suggests AmB enhances SARS-CoV-2 cell entry by overcoming the antiviral effect of the IFITM3 protein. This study further elucidates the role of IFITM3 in viral entry and highlights the potential dangers of treating COVID-19 patients, with invasive pulmonary mucormycosis, using AmB.

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.00519-25?af=R

____

Quantifying the #zoonotic #risk profile of European #influenza A viruses in #swine from 2010 to 2020 inclusive

ABSTRACT

H1 and H3 influenza A viruses (IAVs) circulating in European pigs are markedly distinct from those circulating in other global swine populations. These viruses exhibit significant genetic diversity, further expanded by periodic interspecies transmission of IAVs from humans into pigs, followed by sustained circulation. Several zoonotic IAV infections in humans in Europe have been associated with the 1C lineage of H1 IAVs. Given the predominance of H1 detections in pigs and their zoonotic potential, we quantified antigenic evolution of H1 viruses in European pigs using ferret and pig models and assessed diversity relative to swine IAV vaccine strains. Ferret and swine antisera comparisons revealed no significant differences in antibody responses. Viruses of the 1A.3.3.2 clade exhibited reduced cross-reactivity to human seasonal vaccine strains from 2009. Viruses of the 1B.1.2.2 clade showed no cross-reactivity to the 1978 human seasonal influenza viruses nor to candidate vaccine viruses (CVVs). Clades 1C.2.1 and 1C.2.2 human variant strains had variable cross-reactivity to the tested 1C lineage CVVs, and 1C.2.4 and 1C.2.5 clade viruses exhibited rapid genetic diversification. Many viruses tested were antigenically distant from swine influenza vaccine-representative strains, highlighting the need for updated vaccine formulations. Importantly, age-stratified human serum panels revealed limited population cross-protection to tested viruses, particularly for antigenically heterogenous viruses. These findings quantify the genetic and antigenic diversity of co-circulating IAV lineages and identify specific groups of viruses that may represent a greater risk to animal and public health. These results can be used to inform future pre-pandemic preparedness efforts.

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.00306-25?af=R

____

A replicating recombinant vesicular stomatitis virus #model for dairy #cattle #H5N1 #influenza virus #glycoprotein #evolution

ABSTRACT

A panzootic of highly pathogenic avian influenza (HPAI) H5N1 viruses from clade 2.3.4.4b has triggered a multistate outbreak in US dairy cattle and an unknown number of human infections. HPAI viruses are handled in specialized biocontainment facilities. Ethical considerations limit certain evolution experiments aimed at assessing viral resistance to potential therapeutics. We have developed a replicating recombinant vesicular stomatitis virus (rVSV) where we replaced its glycoprotein with the hemagglutinin (HA) and neuraminidase (NA) genes of a 2.3.4.4b H5N1 virus (rVSV-H5N1dc2024), which enables these experiments to be performed under standard biosafety considerations. This virus grows to high titers and encodes a fluorescent reporter to track infection. We demonstrate the utility of rVSV-H5N1dc2024 in neutralization experiments, the evaluation of antibody escape, and the characterization of resistance mutations to NA inhibitors. rVSV-H5N1dc2024 or similar viruses may accelerate efforts to develop and evaluate interventions against this emerging threat to human and animal health.

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.00389-25?af=R

____

#Phage-induced #protection against lethal #bacterial #reinfection

Significance

In 2021, antimicrobial-resistant bacteria were responsible for 1.14 million deaths and associated with 4.71 million deaths globally. Patients who experience sepsis often face a higher risk of reinfections and hospital readmissions. To combat this crisis, bacteriophages—viruses that infect and kill bacteria—are regaining interest as a potential solution. Here, we show that mice infected with extraintestinal pathogenic Escherichia coli and treated with phage HP3 not only recover from the initial infection but also gain protection against a secondary challenge with the same bacterial strain. The protective effect is dependent on the bacteriolytic action of the phage. These findings shift phages from being solely therapeutic antimicrobials to dual-action immunotherapeutics capable of both clearing and preventing bacterial infections.


Abstract

Bacteriophages, or phages, are viruses that target and infect bacteria. Due to a worldwide rise in antimicrobial resistance (AMR), phages have been proposed as a promising alternative to antibiotics for the treatment of resistant bacterial infections. Up to this point in history, phage use in preclinical animal studies, clinical trials, and emergency-use compassionate care cases has centered around the original observation from 1915 showing phage as lytic agent, and thus a treatment that kills bacteria. Here, we describe an activity associated with phage therapy that extends beyond lytic activity that results in long-term protection against reinfection. This activity is potent, providing almost complete protection against a second lethal infection for animals treated with phage therapy. The activity also reduced infection burden an astounding billion-fold over the control. Reinfection protection requires phage lytic killing of its target bacterium but is independent of additional phage therapy. The effect is not driven by phage alone, lingering phage resistors, or a sublethal inoculum. In vitro phage-lysed bacteria provide partial protection, suggesting a combination of phage-induced lytic activity and immune stimulation by phage treatment is responsible for the effect. These observations imply certain phages may induce host adaptive responses following the lysis of the infecting bacteria. This work suggests phage therapy may contain a dual-action effect, an initial treatment efficacy followed by a long-term protection against reoccurring infection, a therapeutic-vaccination mechanism of action.

Source: Proceedings of the National Academy of Sciences of the United States of America, https://www.pnas.org/doi/abs/10.1073/pnas.2423286122?af=R

____

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt}

A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments: M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic, expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries. The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat.1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts, including vertical transmissions, neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential.5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in extra-Amazonian Brazil, highlighting a potential synergistic mechanism of CNS invasion facilitated by HIV-induced immune dysregulation.

(...)


____

Persistence of #SARS-CoV-2 #Alpha #Variant in White-Tailed #Deer, #Ohio, USA

Abstract

Free-ranging white-tailed deer (WTD) are highly susceptible to the SARS-CoV-2 virus. Through an opportunistic sampling of WTD in northeast Ohio, USA, during January–March 2023, we identified 6 SARS-CoV-2 lineages from 36 sequences using the pangolin lineages tool, including the B.1.1.7 lineage (Alpha variant) and BQ.1.1, BQ.1.1.63, BQ.1.1.67, BQ.1.23, and XBB.1.5.35 lineages (Omicron variant). The Alpha variant, introduced by a single human-to-deer transmission event, was detected in 5 WTD in January 2023, more than 1 year after the most recent detection of the Alpha variant in humans in Ohio (August 2021). A genetically similar B.1.1.7 lineage virus from WTD in a nearby county in Pennsylvania was positioned with our Ohio deer transmission cluster, suggesting deer-to-deer transmission. The persistence of the Alpha variant in WTD in Ohio warrants continued surveillance to monitor if WTD can become a reservoir for displaced SARS-CoV-2 variants.

Source: US Centers for Disease Control and Prevention, https://wwwnc.cdc.gov/eid/article/31/7/24-1922_article

____

#Risk #evaluation of newly emerging #flu viruses based on genomic #sequences and AI

Abstract

The recent resurgence of highly pathogenic avian influenza H5N1 viruses in North America and Europe has heightened global concerns regarding potential influenza pandemics. Despite significant progress in the surveillance and prevention of emerging influenza viruses, effective tools for rapid and accurate risk assessment remain limited. Here, we present FluRisk, an innovative computational framework that integrates viral genomic data with artificial intelligence (AI) to enable rapid and comprehensive risk evaluation of emerging influenza strains. FluRisk incorporates a curated database of over 1,000 experimentally validated molecular markers linked to key viral phenotypes, including mammalian adaptation, mammalian virulence, mammalian transmission, human receptor-binding preference, and antiviral drug resistance. Leveraging these markers, we developed three state-of-the-art machine learning models to predict human adaptation, mammalian virulence, and human receptor-binding potential, all of which demonstrated superior performance compared to traditional approaches such as BLAST, prior models, and baseline classifiers. In addition, a reference-based method was implemented to provide preliminary estimates of human transmissibility and resistance to six commonly used antiviral drugs. To facilitate broad accessibility and practical application, we developed a user-friendly web server that integrates both the molecular marker atlas and predictive tools for influenza virus phenotyping (available at: http://www.computationalbiology.cn/FluRisk/#/). This computational platform offers a valuable resource for the timely risk assessment of emerging influenza viruses and supports global influenza surveillance efforts.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.04.18.649608v2

____

Tuesday, June 3, 2025

#Influenza at the #human - #animal #interface - #Summary and #risk #assessment, from 23 April to 27 May 2025 (#WHO, June 3 '25)

 


New human cases{2}: 

-- From 23 April to 27 May 2025, based on reporting date, the detection of influenza A(H5N1) in three humans, the detection of influenza A(H9N2) virus in eight humans and the detection of influenza A(H10N3) in one human were reported officially. 

-- Circulation of influenza viruses with zoonotic potential in animals: 

- High pathogenicity avian influenza (HPAI) outbreaks in poultry and non-poultry animals continue to be reported to the World Organisation for Animal Health (WOAH).{3} 

- The Food and Agriculture Organization of the United Nations (FAO) also provides a global update on avian influenza viruses with pandemic potential.{4} 

-- Risk assessment{5}: 

- Sustained human to human transmission has not been reported in these events. Based on information available at the time of the risk assessment, the overall public health risk from currently known influenza viruses circulating at the human-animal interface has not changed and remains low. 

- The occurrence of sustained human-to-human transmission of the viruses characterized so far from these events is currently considered unlikely

- Human infections with viruses of animal origin are infrequent, and they are not unexpected at the human-animal interface.  

-- IHR compliance

- All human infections caused by a new influenza subtype are required to be reported under the International Health Regulations (IHR, 2005).{6} 

- This includes any influenza A virus that has demonstrated the capacity to infect a human and its haemagglutinin (HA) gene (or protein) is not a mutated form of those, i.e. A(H1) or A(H3), circulating widely in the human population. 

- Information from these notifications is critical to inform risk assessments for influenza at the human-animal interface.  


Avian influenza viruses in humans 

Current situation:  

Since the last risk assessment of 22 April 2025, laboratory-confirmed human cases of A(H5N1) infection were reported to WHO from Bangladesh and China. 

-- A(H5N1), Bangladesh 

A human infection with an H5 clade 2.3.2.1a A(H5N1) virus was detected in a sample collected from a child in Khulna Division in April 2025, who recovered from his illness. Genetic sequence data are available in GISAID (E EPI_ISL_19875512; submission date 18 May 2025; Institute of Epidemiology, Disease Control & Research (IEDCR); Virology - National Influenza Centre (NIC)). 

WHO was notified of this case on 4 May 2025. In March 2025, an avian influenza A(H5N1) outbreak was reported in poultry in the same district (Jessore) where the case resides.{7} 

A second human infection with an H5 clade 2.3.2.1a A(H5N1) virus was retrospectively detected in a sample collected from a child in Khulna Division in February 2025, who recovered from his illness, according to genetic sequence data available in GISAID (EPI_ISL_19882255;  submission date 26 May 2025; Institute of Epidemiology, Disease Control & Research (IEDCR); Virology - National Influenza Centre (NIC)). WHO was notified of this case on 27 May 2025. 

-- A(H5N1), China 

On 10 May 2025, China notified WHO of one confirmed case of human infection with an avian influenza A(H5N1) virus in an adult traveling from Viet Nam that was detected through routine screening at the port of entry in China

The case was admitted to hospital in China on 7 April and had recovered at the time of notification. 

The likely source of exposure was domestic poultry at the case’s home. 

According to reports received by WOAH, various influenza A(H5) subtypes continue to be detected in wild and domestic birds in Africa, the Americas, Asia and Europe. 

Infections in non-human mammals are also reported, including in marine and terrestrial mammals.{8} 

A list of bird and mammalian species affected by HPAI A(H5) viruses is maintained by FAO.{9}


Risk Assessment for avian influenza A(H5) viruses:  

-- 1. What is the current global public health risk of additional human cases of infection with avian influenza A(H5) viruses?  

- Most human cases so far have been documented as infections in people exposed to A(H5) viruses, for example, through contact with infected poultry or contaminated environments, including live poultry markets, and occasionally infected mammals and contaminated environments. 

- While the viruses continue to be detected in animals and related environments humans are exposed to, further human cases associated with such exposures are expected but unusual. 

- The impact for public health if additional cases are detected is minimal

- The current overall global public health risk of additional human cases is low

-- 2. What is the likelihood of sustained human-to-human transmission of currently circulating avian influenza A(H5) viruses?  

- No sustained human-to-human transmission has been identified associated with the recent reported human infections with avian influenza A(H5). 

- There has been no reported human-to-human transmission of A(H5N1) viruses since 2007, although there may be gaps in investigations. 

- In 2007 and the years prior, small clusters{10} of A(H5) virus infections in humans were reported, including some involving health care workers, where limited human-to-human transmission could not be excluded; however, sustained human-to-human transmission was not reported.  

- Available evidence suggests that the currently circulating influenza A(H5) viruses have not acquired the ability to efficiently transmit between people, therefore the likelihood of sustained human-tohuman transmission is thus currently considered unlikely at this time.  

-- 3. What is the likelihood of international spread of avian influenza A(H5) viruses by travellers?  

- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. If this were to occur, further communitylevel spread is considered unlikely as current evidence suggests these viruses have not acquired the ability to transmit easily among humans.  


-- A(H9N2), China 

- Since the last risk assessment of 22 April 2025, eight human cases of infection with A(H9N2) influenza viruses were notified to WHO from China on 10 May 2025. 

- The cases were detected in Guizhou (two), Hunan (four) and Yunnan (one) provinces and Chongqing municipality (one). 

- Seven cases were in children

- All cases had symptom onset in April 2025. 

- One of the cases (a child) was hospitalized with pneumonia and a respiratory syncytial virus infection at the time of detection but had recovered at the time of reporting. 

- The other cases involved mild illnesses, were detected through the influenza-like illness (ILI) surveillance system, and the cases have recovered. 

- All cases but one had a known history of exposure to poultry prior to the onset of symptoms. 

- In all but one of the cases with known poultry exposure, environmental samples collected from areas associated with the cases tested positive for influenza A(H9) virus. 

- No further cases were detected among contacts of these cases and there was no epidemiological link between the cases.  


Risk Assessment for avian influenza A(H9N2):  

-- 1. What is the global public health risk of additional human cases of infection with avian influenza A(H9N2) viruses?  

- Most human cases follow exposure to the A(H9N2) virus through contact with infected poultry or contaminated environments. 

- Most human infections of A(H9N2) to date have resulted in mild clinical illness. 

- Nearly 130 human infections with A(H9N2) cases have been reported to date since 2003, and six of these have been severe or fatal and three of these were known to have underlying medical conditions. 

- Since the virus is endemic in poultry in multiple countries in Africa and Asia{11}, further human cases associated with exposure to infected poultry are expected but remain unusual. 

- The impact to public health if additional cases are detected is minimal. 

- The overall global public health risk of additional human cases is low. 


-- 2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H9N2) viruses?  

- At the present time, no sustained human-to-human transmission has been identified associated with the event described above. 

- Current evidence suggests that influenza A(H9N2) viruses from these cases have not acquired the ability of sustained transmission among humans, therefore sustained human-to-human transmission is thus currently considered unlikely.  


-- 3. What is the likelihood of international spread of avian influenza A(H9N2) virus by travellers?  

- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

- If this were to occur, further community level spread is considered unlikely as current evidence suggests the A(H9N2) virus subtype has not acquired the ability to transmit easily among humans.  


-- A(H10N3), China 

- On 10 May 2025, China notified WHO of one confirmed case of human infection with avian influenza A(H10N3) virus in an adult from Shaanxi province. 

- The case developed symptoms on 13 April 2025, was admitted to hospital on 18 April with pneumonia and was improving at the time of notification. 

- According to the notification, the case had exposure to backyard poultry

- No additional cases have been reported among family members. 

- Environmental samples collected from the backyard tested negative for influenza A(H10) virus. 


Risk Assessment for avian influenza A(H10N3):  

-- 1. What is the global public health risk of additional human cases of infection with avian influenza  A(H10N3) viruses?  

- Human infections with avian influenza A(H10) viruses have been detected and reported previously.  

- The circulation and epidemiology of these viruses in birds have been previously reported.{12} 

- Avian influenza A(H10N3) viruses with different genetic characteristics have been detected previously in wild birds since the 1970s and more recently spilled over to poultry in some countries. 

- As long as the virus continues to circulate in birds, further human cases can be expected but remain unusual. 

- The impact to public health if additional sporadic cases are detected is minimal. 

- The overall global public health risk of additional sporadic human cases is low.   


-- 2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H10N3)  viruses?  

- No sustained human-to-human transmission has been identified associated with the event described  above or past events with human cases of influenza A(H10N3) viruses. 

- Current epidemiologic and virologic evidence suggests that contemporary influenza A(H10N3) viruses assessed by the Global Influenza Surveillance and response System (GISRS) have not acquired the ability of sustained transmission among humans, therefore sustained human-to-human transmission is thus currently considered unlikely.   


-- 3. What is the likelihood of international spread of avian influenza A(H10N3) virus by travellers?  

- Should infected individuals from affected areas travel internationally, their infection may be  detected in another country during travel or after arrival. 

- If this were to occur, further community  level spread is considered unlikely based on current limited evidence. 


Overall risk management recommendations

Surveillance and investigations 

Due to the constantly evolving nature of influenza viruses, WHO continues to stress the importance of global strategic surveillance in animals and humans to detect virologic, epidemiologic and clinical changes associated with circulating influenza viruses that may affect human (or animal) health. Continued vigilance is needed within affected and neighbouring areas to detect infections in animals and humans. Close collaboration with the animal health and environment sectors is essential to understand the extent of the risk of human exposure and to prevent and control the spread of animal influenza. WHO has published guidance on surveillance for human infections with avian influenza A(H5) viruses. 

As the extent of influenza virus circulation in animals is not clear, epidemiologic and virologic surveillance and the follow-up of suspected human cases should continue systematically. Guidance on investigation of non-seasonal influenza and other emerging acute respiratory diseases has been published on the WHO website. 

Countries should increase avian influenza surveillance in domestic and wild birds, enhance surveillance for early detection in cattle populations in countries where HPAI is known to be circulating, include HPAI as a differential diagnosis in non-avian species, including cattle and other livestock populations, with high risk of exposure to HPAI viruses; monitor and investigate cases in non-avian species, including livestock, report cases of HPAI in all animal species, including unusual hosts, to WOAH and other international organizations, share genetic sequences of avian influenza viruses in publicly available databases, implement preventive and early response measures to break the HPAI transmission cycle among animals through movement restrictions of infected livestock holdings and strict biosecurity measures in all holdings, employ good production and hygiene practices when handing animal products, and protect persons in contact with suspected/infected animals.{13}  

• When there has been human exposure to a known outbreak of an influenza A virus in domestic poultry, wild birds or other animals – or when there has been an identified human case of infection with such a virus – enhanced surveillance in potentially exposed human populations becomes necessary. Enhanced surveillance should consider the health care seeking behaviour of the population, and could include a range of active and passive health care and/or communitybased approaches, including: enhanced surveillance in local influenza-like illness (ILI)/SARI systems, active screening in hospitals and of groups that may be at higher occupational risk of exposure, and inclusion of other sources such as traditional healers, private practitioners and private diagnostic laboratories. 

Vigilance for the emergence of novel influenza viruses of pandemic potential should be maintained at all times including during a non-influenza emergency. In the context of the cocirculation of SARS-CoV-2 and influenza viruses, WHO has updated and published practical guidance for integrated surveillance. 


Notifying WHO 

All human infections caused by a new subtype of influenza virus are notifiable under the International Health Regulations (IHR, 2005).{14} State Parties to the IHR (2005) are required to immediately notify WHO of any laboratory-confirmed{15} case of a recent human infection caused by an influenza A virus with the potential to cause a pandemic{16}. Evidence of illness is not required for this report. 

WHO published the case definition for human infections with avian influenza A(H5) virus requiring notification under IHR (2005): https://www.who.int/teams/global-influenzaprogramme/avian-influenza/case-definitions


Virus sharing and risk assessment 

It is critical that these influenza viruses from animals or from people are fully characterized in appropriate animal or human health influenza reference laboratories. Under WHO’s Pandemic Influenza Preparedness (PIP) Framework, Member States are expected to share influenza viruses with pandemic potential on a timely basis{17} with a WHO Collaborating Centre for influenza of GISRS. The viruses are used by the public health laboratories to assess the risk of pandemic influenza and to develop candidate vaccine viruses.  

The Tool for Influenza Pandemic Risk Assessment (TIPRA) provides an in-depth assessment of risk associated with some zoonotic influenza viruses – notably the likelihood of the virus gaining human-to-human transmissibility, and the impact should the virus gain such transmissibility. TIPRA maps relative risk amongst viruses assessed using multiple elements. The results of TIPRA complement those of the risk assessment provided here, and those of prior TIPRA analyses will be published at http://www.who.int/teams/global-influenza-programme/avian-influenza/toolfor-influenza-pandemic-risk-assessment-(tipra).  


Risk reduction 

Given the observed extent and frequency of avian influenza in poultry, wild birds and some wild and domestic mammals, the public should avoid contact with animals that are sick or dead from unknown causes, including wild animals, and should report dead birds and mammals or request their removal by contacting local wildlife or veterinary authorities.  

Eggs, poultry meat and other poultry food products should be properly cooked and properly handled during food preparation. Due to the potential health risks to consumers, raw milk should be avoided. WHO advises consuming pasteurized milk. If pasteurized milk isn’t available, heating raw milk until it boils makes it safer for consumption. 

WHO has published practical interim guidance to reduce the risk of infection in people exposed to avian influenza viruses. 


Trade and travellers 

WHO advises that travellers to countries with known outbreaks of animal influenza should avoid farms, contact with animals in live animal markets, entering areas where animals may be slaughtered, or contact with any surfaces that appear to be contaminated with animal excreta. Travelers should also wash their hands often with soap and water. All individuals should follow good food safety and hygiene practices.  

WHO does not advise special traveller screening at points of entry or restrictions with regards to the current situation of influenza viruses at the human-animal interface. For recommendations on safe trade in animals and related products from countries affected by these influenza viruses, refer to WOAH guidance.  


Links:  

WHO Human-Animal Interface web page https://www.who.int/teams/global-influenza-programme/avian-influenza 

WHO Influenza (Avian and other zoonotic) fact sheet https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic) 

WHO Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases https://www.who.int/publications/i/item/WHO-WHE-IHM-GIP-2018.2 

WHO Public health resource pack for countries experiencing outbreaks of influenza in animals:  https://www.who.int/publications/i/item/9789240076884 

Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO  https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virus 

Avian Influenza A(H7N9) Information https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-influenza-a-(h7n9)virus 

World Organisation of Animal Health (WOAH) web page: Avian Influenza  https://www.woah.org/en/home/ 

Food and Agriculture Organization of the United Nations (FAO) webpage: Avian Influenza https://www.fao.org/animal-health/avian-flu-qa/en/ 

OFFLU http://www.offlu.org/

____

{1} This summary and assessment covers information confirmed during this period and may include information received outside of this period. 

{2} For epidemiological and virological features of human infections with animal influenza viruses not reported in this assessment, see the reports on human cases of influenza at the human-animal interface published in the Weekly Epidemiological Record here.  

{3} World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2

{4} Food and Agriculture Organization of the United Nations (FAO). Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential

{5} World Health Organization (2012). Rapid risk assessment of acute public health events. World Health Organization. Available at: https://iris.who.int/handle/10665/70810

{6} World Health Organization. Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005).   

{7} WOAH. WAHIS. Bangladesh - High pathogenicity avian influenza viruses (poultry) (Inf. with). Event 6351. Available at: https://wahis.woah.org/#/in-event/6351/dashboard

{8} World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2

{9} Food and Agriculture Organization of the United Nations. Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential/bird-species-affected-by-h5nx-hpai/en

{10} A cluster is defined as two or more persons with onset of symptoms within the same 14-day period and who are associated with a specific setting, such as a classroom, workplace, household, extended family, hospital, other residential institution, military barracks or recreational camp. 

{11} Food and Agriculture Organization of the United Nations (FAO). Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential

{12} Wang X, Yu H, Ma Y, Zhang P, Wang X, Liang J et al. 2025. The novel H10N3 avian influenza virus acquired airborne transmission among chickens: an increasing threat to public health. [Pre-print] mBio 16:e02363-24. https://doi.org/10.1128/mbio.02363-24

{13} World Organisation for Animal Health. Statement on High Pathogenicity Avian Influenza in Cattle, 6 December 2024. Available at: https://www.woah.org/en/high-pathogenicity-avian-influenza-hpai-in-cattle/

{14} World Health Organization. Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005).    

{15} World Health Organization. Manual for the laboratory diagnosis and virological surveillance of influenza (2011). Available at: https://apps.who.int/iris/handle/10665/44518 

{16} World Health Organization. Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits, 2nd edition. Available at: https://iris.who.int/handle/10665/341850 

{17} World Health Organization. Operational guidance on sharing influenza viruses with human pandemic potential (IVPP) under the Pandemic Influenza Preparedness (PIP) Framework (2017). Available at: https://apps.who.int/iris/handle/10665/259402

___

Source: World Health Organization, https://www.who.int/publications/m/item/influenza-at-the-human-animal-interface-summary-and-assessment--27-may-2025

____

Single-Cell #Analysis of Host Responses in #Bovine #Milk Somatic Cells (bMSCs) Following #HPAIV Bovine #H5N1 #Influenza Exposure

Abstract

The 2024 outbreak of highly pathogenic avian influenza virus (HPAIV) H5N1 in U.S. dairy cattle presented an unprecedented scenario where the virus infected bovine mammary glands and was detected in milk, raising serious concerns for public health and the dairy industry. Unlike previously described subclinical influenza A virus (IAV) infections in cattle, H5N1 infection induced severe clinical symptoms, including respiratory distress, mastitis, and abnormal milk production. To understand the host immune responses and changes, particularly in the mammary gland, we performed single-cell RNA sequencing analysis on bovine milk somatic cells (bMSCs) in vitro exposed to an H5N1 isolate from an infected dairy farm. We identified ten distinct cell clusters and observed a shift toward type-2 immune responses, characterized by T cells expressing IL13 and GATA3, and three different subtypes of epithelial cells based on the expression of genes associated with milk production. Our study revealed temporal dynamics in cytokine expression, with a rapid decline in luminal epithelial cells and an increase in macrophages and dendritic cells, suggesting a role in increased antigen presentation. While viral RNA was detected in bulk-exposed bMSC samples via qRT-PCR, no viral reads were observed in the scRNA-seq data, indicating that the immune responses captured may be due to exposure to viral components rather than productive infection. This research fills a critical gap in understanding the immune responses of bovine mammary glands to H5N1 exposure and highlights the need for further investigation into therapeutic strategies for managing such outbreaks.

Source: Viruses, https://www.mdpi.com/1999-4915/17/6/811

____

Monday, June 2, 2025

Recurrent #MERS-CoV #Transmission in #Saudi Arabia– Renewed Lessons in #Healthcare #Preparedness and Surveillance

{Excerpt}

The World Health Organization (WHO) had recently announced on May 12, 2025, the reporting of nine new laboratory-confirmed cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Saudi Arabia [1]. This announcement is a sobering reminder that while the global community remains focused on emergent threats like avian influenza or post-pandemic resilience, endemic zoonotic diseases like MERS-CoV may continue to circulate, evolve, and exploit gaps in infection prevention.

(...)

Source: Journal of Epidemiology and Global Health, https://link.springer.com/article/10.1007/s44197-025-00426-6

____

#Philippines - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification [FINAL]

The samples collected in two (2) wild bird species: Red Shank (Tringa totanus) and Arctic Warbler (Phylloscopus borealis), that tested positive for Notifiable Avian Influenza Subtype H5N1 were part of the regular wildlife disease surveillance activity being conducted by the wetland park. In response, additional samples were collected from wild birds, and all tested negative for Avian Influenza. Comprehensive surveillance and sample collection efforts in the surrounding domestic poultry population also confirmed no presence of Avian Influenza.

Source: WOAH, https://wahis.woah.org/#/in-review/6523

____

#Latvia - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

HPAI H5N1 confirmed in backyard poultry farm with approx. 190 birds (laying hens). Susupicion date 27/05/2025 - some birds with neurological signs, one dead. Laboratory diagnosis confirmed at the Latvian National Reference Laboratory for avian influenza.

Source: WOAH, https://wahis.woah.org/#/in-review/6528

____

Sunday, June 1, 2025

The Jabach Altarpiece, Albrecht Durer (1504)

 


Public Domain.

Source: WikiArt, https://www.wikiart.org/en/albrecht-durer/the-jabach-altarpiece-1504

____

Saturday, May 31, 2025

#Coronavirus Disease Research #References (by AMEDEO, May 31 '25)


 

    Am J Respir Crit Care Med

  1. KRISHNAN JA, Cao B, Chotirmall SH, Ely EW, et al
    Using the 2024 NASEM Definition of Long COVID: Implications for Pulmonary and Critical Care Medicine.
    Am J Respir Crit Care Med. 2025.
    PubMed        


    BMJ

  2. IBRAHIM S, Siemieniuk RAC, Oliveros MJ, Islam N, et al
    Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis.
    BMJ. 2025;389:e081165.
    PubMed         Abstract available

  3. BOSAEED M, Alraddadi BM
    Navigating the complexities of mild and moderate covid-19 treatment.
    BMJ. 2025;389:r1016.
    PubMed        

  4. TANNE JH
    US no longer recommends covid-19 vaccinations for pregnant women or children.
    BMJ. 2025;389:r1104.
    PubMed        

  5. O'DOWD A, Iacobucci G
    Covid-19: Early call to test healthcare staff was ignored, inquiry hears.
    BMJ. 2025;389:r1092.
    PubMed        


    Clin Infect Dis

  6. WOLFE CR, Cohen J, Mahoney K, Holmes A, et al
    Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY).
    Clin Infect Dis. 2025 May 24:ciaf265. doi: 10.1093.
    PubMed         Abstract available


    Emerg Infect Dis

  7. ROSAS IO, Benitez A, McKinnell JA, Shah R, et al
    Long-Term Clinical Outcomes of Adults Hospitalized for COVID-19 Pneumonia.
    Emerg Infect Dis. 2025;31:1158-1168.
    PubMed         Abstract available


    Int J Infect Dis

  8. DEBIE Y, Verbruggen L, Peeters M, van Dam PA, et al
    mRNA COVID-19 vaccines induce superior IgA titers in cancer patients compared to viral vector vaccines: Implications for immunization strategies.
    Int J Infect Dis. 2025 May 23:107939. doi: 10.1016/j.ijid.2025.107939.
    PubMed         Abstract available


    J Infect

  9. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
    Corrigendum to "Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: A cohort study" [J Infect 90 (2025) 106497].
    J Infect. 2025;91:106522.
    PubMed        


    J Med Virol

  10. PIAZZESE C, Williams S, Brentall A, Kele B, et al
    Analysis of Variants' Dynamic Using the CLIMB Database in COVID-19 Patients Admitted to Hospitals of Barts Health NHS Trust.
    J Med Virol. 2025;97:e70402.
    PubMed         Abstract available

  11. LIU K, Rao J, Hu X, Sun H, et al
    Maternal Vaccination and Protective Immunity Against SARS-CoV-2 Infection in Pups.
    J Med Virol. 2025;97:e70418.
    PubMed         Abstract available

  12. PENG W, Wei X, Wu Y, Shi C, et al
    Dynamic Molecular Changes in Brain, Lung, and Heart of Hamsters Infected With SARS-CoV-2: Insights From a Severe and Recovery Phase Model.
    J Med Virol. 2025;97:e70410.
    PubMed         Abstract available

  13. ALIYARI SR, Shanaa J, Yu D, Yamamoto M, et al
    Suppression of Monkeypox Virus by Downregulation of Fatty Acid Synthase and Upregulation of Cholesterol-25 Hydroxylase.
    J Med Virol. 2025;97:e70403.
    PubMed         Abstract available


    J Virol

  14. WANG Y, Tong W, Qin W, Yang X, et al
    Midnolin inhibits coronavirus proliferation by degrading viral proteins.
    J Virol. 2025 May 29:e0036625. doi: 10.1128/jvi.00366.
    PubMed         Abstract available

  15. GUO L, Duan X, Li J, Hao Z, et al
    YIPF5 is an essential host factor for porcine epidemic diarrhea virus double-membrane vesicle formation.
    J Virol. 2025 May 27:e0032025. doi: 10.1128/jvi.00320.
    PubMed         Abstract available

  16. POGANY J, Inaba J-i, Liu Y, Nagy PD, et al
    Screening bacterial effectors and human virus proteins in yeast to identify host factors driving tombusvirus RNA recombination: a role for autophagy and membrane phospholipid content.
    J Virol. 2025 May 27:e0166124. doi: 10.1128/jvi.01661.
    PubMed         Abstract available


    Lancet Infect Dis

  17. FOLEGATTI PM, Pepin S, Tabar C, Fries K, et al
    Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study.
    Lancet Infect Dis. 2025 May 21:S1473-3099(25)00153.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  18. LAMBROU AS, South E, Midgley CM, Harrington C, et al
    Update on the Epidemiology of Middle East Respiratory Syndrome Coronavirus - Worldwide, 2017-2023.
    MMWR Morb Mortal Wkly Rep. 2025;74:313-320.
    PubMed         Abstract available


    Nature

  19. HILL R, Yin Y, Stein C, Wang X, et al
    The pivot penalty in research.
    Nature. 2025 May 28. doi: 10.1038/s41586-025-09048.
    PubMed         Abstract available

  20. ZHAO Y, Zheng B, Saunois M, Ciais P, et al
    Air pollution modulates trends and variability of the global methane budget.
    Nature. 2025 May 28. doi: 10.1038/s41586-025-09004.
    PubMed         Abstract available


    Radiologia (Engl Ed)

  21. PEREZ LAENCINA M, Plasencia Martinez JM, Sanchez Canales M, Jimenez Pulido C, et al
    A commercial AI tool untrained for COVID-19 demonstrates slight improvement in the interpretation of COVID-19 pneumonia x-rays, especially among inexperienced readers.
    Radiologia (Engl Ed). 2025;67:273-286.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, May 31 '25)


 

    Arch Virol

  1. LIU X
    ACE2, a therapeutic target of COVID-19, needs to be treated with caution.
    Arch Virol. 2025;170:143.
    PubMed         Abstract available


    BMJ

  2. IBRAHIM S, Siemieniuk RAC, Oliveros MJ, Islam N, et al
    Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis.
    BMJ. 2025;389:e081165.
    PubMed         Abstract available


    J Immunol

  3. DING C, Chen Q, Shi Y, Liu J, et al
    Impact of CD4+ T cell and TCR repertoires on SARS-CoV-2-Specific antibody responses in PLWH following COVID-19 vaccination.
    J Immunol. 2025 Apr 15:vkae040. doi: 10.1093.
    PubMed         Abstract available


    J Infect

  4. PETER RS, Sedelmaier L, Nieters A, Brockmann SO, et al
    Symptom burden and post-COVID-19 syndrome 24 months following SARS-CoV-2 infection: Longitudinal population-based study.
    J Infect. 2025;90:106500.
    PubMed         Abstract available

  5. HOOG M, Westrhenen ESH, Winkel AM, Jong MD, et al
    Impact of co-infection with SARS-CoV-2 and other respiratory viruses on illness: Pooled analyses of 11 COVID-19 cohorts.
    J Infect. 2025 May 9:106501. doi: 10.1016/j.jinf.2025.106501.
    PubMed         Abstract available

  6. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
    Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: a cohort study.
    J Infect. 2025 Apr 30:106497. doi: 10.1016/j.jinf.2025.106497.
    PubMed         Abstract available

  7. OVERTON CE, Fyles M, Mellor J, Paton RS, et al
    SARS-CoV-2 test sensitivity and duration of positivity in the UK during the 2023/2024 Winter: A prospective cohort study based on self-reported data.
    J Infect. 2025;90:106485.
    PubMed         Abstract available

  8. CHEN R, Hao Z, Ye J, Zhao X, et al
    Decoding Post-Mortem Infection Dynamics of SARS-CoV-2, IAV and RSV: New Insights for Public Health and Emerging Infectious Diseases Management.
    J Infect. 2025 Apr 21:106489. doi: 10.1016/j.jinf.2025.106489.
    PubMed         Abstract available


    J Virol

  9. ZHANG Q, Zhang L, Li J, Zhang W, et al
    hnRNPM regulates influenza A virus replication through distinct mechanisms in human and avian cells: implications for cross-species transmission.
    J Virol. 2025 May 28:e0006725. doi: 10.1128/jvi.00067.
    PubMed         Abstract available


    JAMA

  10. MOIN EE, Seewald NJ, Halpern SD
    Use of Life Support and Outcomes Among Patients Admitted to Intensive Care Units.
    JAMA. 2025 Apr 14:e252163. doi: 10.1001/jama.2025.2163.
    PubMed         Abstract available


    PLoS Comput Biol

  11. ZHANG R, Tai J, Yao Q, Yang W, et al
    Behavior-driven forecasts of neighborhood-level COVID-19 spread in New York City.
    PLoS Comput Biol. 2025;21:e1012979.
    PubMed         Abstract available

  12. MEDINA CM, Palacios JA, Minin VM
    Accounting for reporting delays in real-time phylodynamic analyses with preferential sampling.
    PLoS Comput Biol. 2025;21:e1012970.
    PubMed         Abstract available


    PLoS One

  13. REHMAN N, Mbuagbaw L, Mertz D, Muraca GM, et al
    Association between virtual visits and health outcomes of people living with HIV: A cross-sectional study.
    PLoS One. 2025;20:e0315880.
    PubMed         Abstract available

  14. DHAR B, Sajid M
    On improving public health after COVID-19 epidemic: A fractal-fractional mathematical solutions with short memory effect and efficient optimal strategies.
    PLoS One. 2025;20:e0321195.
    PubMed         Abstract available

  15. KUANG D, Gao X, Du N, Huang J, et al
    Wastewater surveillance as a predictive tool for COVID-19: A case study in Chengdu.
    PLoS One. 2025;20:e0324521.
    PubMed         Abstract available

  16. HONDA R, Abe T, Baba T, Araki Y, et al
    Dissemination of local sub-variants of SARS-CoV-2 detected by detailed mutation analysis in wastewater-based epidemiology.
    PLoS One. 2025;20:e0317076.
    PubMed         Abstract available

  17. HAN Z, Chen M, Wang Y
    The impact of COVID-19 stress on nurses' organizational deviance: A moderated mediation model.
    PLoS One. 2025;20:e0324992.
    PubMed         Abstract available

  18. CAZER CL, Lawless JW, Mehta P, Wagner B, et al
    Prevalence of SARS-CoV-2 infection and immunity in a New York county in 2022 reveals frequent asymptomatic or undiagnosed infections.
    PLoS One. 2025;20:e0323659.
    PubMed         Abstract available

  19. AXEN I, Weiss N, Skillgate E
    Manual therapists in Sweden during the COVID-19 pandemic -they remained in business, but how was their work environment and practice impacted?
    PLoS One. 2025;20:e0324245.
    PubMed         Abstract available

  20. HEYDARI P, Meyer MN, Chabris CF
    Medical rationing choices of laypeople and clinicians are often illogical and inconsistent with their own stated preferences.
    PLoS One. 2025;20:e0322242.
    PubMed         Abstract available

  21. ALTARE C, Kim K, Spiegel PB
    "Everything had stopped, no meeting, no gathering": Social interactions during the COVID-19 pandemic in the Central African Republic, the Democratic Republic of Congo, and Bangladesh.
    PLoS One. 2025;20:e0323108.
    PubMed         Abstract available

  22. KENGNE KAMGA LS, Voordouw ACG, De Vries MC, Kemper S, et al
    The citizen's perception of a shared responsibility during the COVID-19 management: Insights from a focus group study across four European countries.
    PLoS One. 2025;20:e0322019.
    PubMed         Abstract available

  23. RUSSO FF
    Testing policies during an epidemic: An economic analysis.
    PLoS One. 2025;20:e0322292.
    PubMed         Abstract available

  24. POORBAUGH J, Sims JT, Zhang L, Chang CY, et al
    Serum IL-6 and PTX3 predict severe outcome from COVID-19 in ambulatory subjects: Impact for future therapeutic decisions.
    PLoS One. 2025;20:e0324242.
    PubMed         Abstract available

  25. MANUEL DG, Bennett C, Brown E, Buckeridge DL, et al
    Developing an evaluation framework for public health environmental surveillance: Protocol for an international, multidisciplinary Delphi consensus study.
    PLoS One. 2025;20:e0310342.
    PubMed         Abstract available

  26. SHIMIZU HE, Gomes AMT, Apostolidis T
    The social representations of Covid-19 among primary health care' users in the Federal district, Brazil: A psychosocial approach.
    PLoS One. 2025;20:e0323568.
    PubMed         Abstract available

  27. MA X, Huang T, Song Y, Pan H, et al
    Bioinformatics and system biology approach to discover the common pathogenetic processes between COVID-19 and chronic hepatitis B.
    PLoS One. 2025;20:e0323708.
    PubMed         Abstract available

  28. NYONGESA V, Kathono J, Mwavua S, Nyamai D, et al
    "If I tell you my problems, how will you perceive me?": A qualitative study of mental health knowledge, barriers, and opportunities for care among Kenyan adolescents during COVID-19.
    PLoS One. 2025;20:e0323907.
    PubMed         Abstract available

  29. SONG MC, Ha J, Park S, Kang H, et al
    Mortality in severe serious adverse events following heterologous and homologous prime-boost vaccination strategies for SARS-CoV-2: A retrospective cohort study.
    PLoS One. 2025;20:e0323736.
    PubMed         Abstract available

  30. NATALIA YA, Molenberghs G, Neyens T, Hens N, et al
    Empirical analysis of COVID-19 confirmed cases, hospitalizations, vaccination, and international travel across Belgian provinces in 2021.
    PLoS One. 2025;20:e0322017.
    PubMed         Abstract available

  31. KULJANCIC D, Amidzic J, Ljubotin L, Siladji D, et al
    Clinical profile of alcohol dependent paintents according to Lesch Typology one year after the Covid-19 pandemic-comparative study.
    PLoS One. 2025;20:e0324851.
    PubMed         Abstract available


  32. Retraction: Comprehensive computational analysis reveals H5N1 influenza virus-encoded miRNAs and host-specific targets associated with antiviral immune responses and protein binding.
    PLoS One. 2025;20:e0325170.
    PubMed        

  33. COLMAN E, Kao R
    The impact of signal variability on COVID-19 epidemic growth rate estimation from wastewater surveillance data.
    PLoS One. 2025;20:e0322057.
    PubMed         Abstract available

  34. WANG CN, Nguyen TTM, Nhieu NL, Chung YC, et al
    Performance evaluation of Vietnamese industrial goods and services during and post-COVID-19 era based on multi-criteria decision-making methods.
    PLoS One. 2025;20:e0323764.
    PubMed         Abstract available

  35. VAN DER MOEREN N, van den Biggelaar R, Gast KB, Verweij JJ, et al
    The added diagnostic value of RT-PCR on faeces for the diagnosis of COVID-19.
    PLoS One. 2025;20:e0322543.
    PubMed         Abstract available

  36. BENTAHAR I, Loubet P, Salipante F, Choquet C, et al
    Respiratory viruses Ct values and association with clinical outcomes among adults visiting the ED with lower respiratory tract infections.
    PLoS One. 2025;20:e0320503.
    PubMed         Abstract available


    Vaccine

  37. RAHIMI HK, Jasim AA, Rezahosseini O, Harboe ZB, et al
    Immunogenicity and adverse effects of pneumococcal vaccines co-administered with influenza or SARS-CoV-2 vaccines in adults: A systematic review and Meta-analysis.
    Vaccine. 2025;59:127293.
    PubMed         Abstract available

  38. QUENTIN E, Ahmed I, Duong CH, Tubert-Bitter P, et al
    Covid-19 Vaccination During Pregnancy in France: a Descriptive Study of Uptake Using the National Healthcare data System.
    Vaccine. 2025;58:127223.
    PubMed         Abstract available

  39. LUPTON D, Whitten T, Tay AK, Beek K, et al
    Mental health and psychosocial factors predicting concerns about the COVID-19 vaccine among refugee background and Australian-born women.
    Vaccine. 2025;58:127251.
    PubMed         Abstract available

  40. AVERIN A, Quinn E, Atwood M, Weycker D, et al
    Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United States.
    Vaccine. 2025;58:127191.
    PubMed         Abstract available

  41. SASAKI E, Hamaguchi I, Hasegawa H, Takahashi Y, et al
    Establishment of a novel adjuvant screening system for the development of intranasal vaccine adjuvants.
    Vaccine. 2025;58:127267.
    PubMed         Abstract available

  42. MOORE DCBC, Nehab MF, Reis AT, Junqueira-Marinho MF, et al
    Childhood vaccine hesitancy: The power of metaphors.
    Vaccine. 2025;58:127221.
    PubMed         Abstract available

  43. PATTYN J, Hanning N, Valckx S, Claessens T, et al
    Investigating the state of vaccine confidence among the general public and parents with children up to 13 years in Flanders (Belgium).
    Vaccine. 2025;58:127250.
    PubMed         Abstract available

  44. MERRITT A, Bansal S
    Prison Vaccination in a pandemic: Geographic disparities and policy insights.
    Vaccine. 2025;58:127218.
    PubMed         Abstract available

  45. PEARCE A, Henery P, Dundas R, Katikireddi SV, et al
    Socio-economic inequalities in uptake and timing of childhood vaccination: Taking a life course approach in an administrative cohort in Scotland.
    Vaccine. 2025;57:127222.
    PubMed         Abstract available

  46. WANG-LU H, Valerio Mendoza OM, Chen S, Geldsetzer P, et al
    Regional mobility and COVID-19 vaccine hesitancy: Evidence from China.
    Vaccine. 2025;58:127179.
    PubMed         Abstract available

  47. STEPANEK L, Nakladalova M, Borikova A, Horakova D, et al
    Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort study.
    Vaccine. 2025;57:127232.
    PubMed         Abstract available

  48. ADAME BJ, Corman SR, Von Feldt PA, Meneses CM, et al
    Reactance as a cause of COVID-19 vaccination hesitancy.
    Vaccine. 2025;57:127209.
    PubMed         Abstract available

  49. ROULEAU I, Issa Kana KDN, Zafack JG, Viger YB, et al
    New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada.
    Vaccine. 2025;57:127217.
    PubMed         Abstract available

  50. MALANGE V, Mohaissen T, Conway KM, Rhoads A, et al
    Influenza vaccination during early pregnancy and risk of major birth defects, US Birth Defects Study To Evaluate Pregnancy exposureS, 2014-2019.
    Vaccine. 2025;59:127297.
    PubMed         Abstract available

  51. SEILER P, Kaplan BS, Brice DC, Duan S, et al
    Altered germinal center responses in mice vaccinated with highly pathogenic avian influenza A(H5N1) virus.
    Vaccine. 2025;60:127311.
    PubMed         Abstract available


    Virology

  52. LENDE SSF, Rothemejer FH, Andreas M, Pedersen ML, et al
    Vectored long-term co-delivery of antibodies for SARS-CoV-2, RSV and Influenza prophylaxis.
    Virology. 2025;610:110573.
    PubMed         Abstract available

History of Mass Transportation: The FS D461 Diesel-Electric Locomotive

 


By Domenvadrouille - Flickr: les pieces de collections, CC BY 2.0, https://commons.wikimedia.org/w/index.php?curid=17692704

Source: WikiPedia, https://it.wikipedia.org/wiki/Locomotiva_FS_D.461

____

#Brazil’s First #H5N1 #Outbreak in Commercial #Poultry: A #Sentinel Event for Cross-Border #Preparedness

Highlight

Brazil’s first confirmed H5N1 outbreak in commercial poultry marks a critical shift in South America’s avian influenza landscape. The event calls for strengthened coordination between animal and human health sectors, improved border surveillance, and early-warning systems to reduce zoonotic risk in regions with growing poultry production and international connectivity.

Source: Journal of Travel Medicine, https://academic.oup.com/jtm/advance-article-abstract/doi/10.1093/jtm/taaf050/8153894?redirectedFrom=fulltext

____

Friday, May 30, 2025

#Evidence of #Viremia in Dairy #Cows Naturally Infected with #Influenza A {#H5N1} Virus, #California, #USA

Abstract

We confirmed influenza A virus (IAV) by PCR in serum from 18 cows on 3 affected dairy farms in California, USA. Our findings indicate the presence of viremia and might help explain IAV transmission dynamics and shedding patterns in cows. An understanding of those dynamics could enable development of IAV mitigation strategies.

Source: US Centers for Disease Control and Prevention, https://wwwnc.cdc.gov/eid/article/31/7/25-0134_article

____

#USA, Monitoring for Avian #Influenza A(#H5) Virus In #Wastewater (US CDC, May 29 '25) {Updated}

 


{Excerpt}

Time Period: May 18, 2025 - May 24, 2025

-- H5 Detection17 sites (5.0%)

- No Detection322 sites (95.0%)

- No samples in last week116 sites






(...)

Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/bird-flu/h5-monitoring/index.html

____

My New Space

Most Popular Posts